In today’s digital era, data is an invaluable asset for businesses, offering opportunities for innovation and competitive advantages. However, effectively monetising data involves navigating complex legal frameworks that govern ownership, protection, and commercialisation. This Article examines key legal provisions under
China Law Vision
China Law Vision, published by AnJie Broad Law Firm, focuses on legal developments and practical issues in Chinese law, including corporate compliance, intellectual property protection, cybersecurity regulations, trade secret enforcement, and criminal law as it relates to business and internet companies. The blog analyzes new laws, judicial interpretations, and regulatory policies affecting domestic and international enterprises operating in China. It also covers risk management strategies for companies, updates on government policies, and case studies illustrating enforcement trends and legal challenges in sectors such as technology, trade, and insurance.
Latest from China Law Vision - Page 3
The Practice and Prospects of China’s Cross-Border Bankruptcy System
Introduction
In recent years, China has actively engaged in international investment and regional cooperation. According to data from the official website of the Ministry of Commerce, PRC, from January to April 2025, Chinese domestic investors conducted non-financial outward foreign direct…
The Impact of the New Company Law on Insurance Corporate Governance
The newly revised Company Law (“New Company Law”) was adopted at the 7th Session of the Standing Committee of the 14th National People’s Congress on December 29, 2023, and has come into effect on July 1, 2024. This article provides…
Latest Development in China’s Criminal Regulation on Intellectual Property
Ⅰ. Introduction
April 26, 2025, marks the 25th “World Intellectual Property Day”, and China also announced the “National Intellectual Property Week” from April 20 to April 26. In the wake of rapidly changing global situation and profound changes unprecedented in…
Opportunities and Challenges of Brazil-China Trade under the Impact of US Tariffs
Authors | Andy See, José Moscati
In April 2025, US President Trump issued Executive Orders 14257 and 14259, announcing the imposition of a 10% reciprocal tariff on several countries and regions, including Brazil, effective 5 April. An additional 10% reciprocal…
Can the “Misleading Sales” Determined by Financial Regulatory Authorities Serve as the Basis for Fraud to Revoke an Insurance Contract?
Core Tip:
The “misleading sales” determined by financial regulatory authorities is not equivalent to “fraud” under civil law. People’s courts should review whether it constitutes “fraud” in accordance with the law, based on the specific circumstances of each case, the…
Practical Guide to Investments in Real Estate Funds by Insurance Companies
Following the release of the Guidelines for the Pilot Filing of Real Estate Private Investment Funds (Trial) (commonly referred to as “Circular No. 4”) by the Asset Management Association of China (AMAC) in February 2023, real estate funds have garnered…
Administrative and Judicial Pathways to Address Malicious Network Content in China
In today’s ever-changing digital ecosystem, the proliferation of false information and even malicious contents has emerged as one of the most pressing challenges to the cyberspace integrity. In recent years, China’s internet regulator and judicial authorities have put efforts in…
Criminal Regulation and Practice of Insurance Fraud in China
On January 3, 2025, the Ministry of Public Security held a press conference in Beijing to report the results of the special crackdown on insurance fraud crimes jointly conducted by the Ministry of Public Security and the National Financial Regulatory…
Interpretation of the Anti-Monopoly Guidelines for Pharmaceutical Sector: Key Risk Considerations
On January 23, 2025, the Anti-Monopoly and Anti-Unfair Competition Commission under China’s State Council officially released the PRC Anti-Monopoly Guidelines for the Pharmaceutical Sector (“the Pharmaceutical Guidelines”). From release of the draft for public comments on August 9, 2024, to…